Trial Profile
Tolerability and pharmacodynamics of AXT 914 (45 or 60 mg/day) vs teriparatide in healthy postmenopausal women
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 08 Sep 2015
Price :
$35
*
At a glance
- Drugs AXT 914 (Primary) ; Teriparatide
- Indications Postmenopausal osteoporosis
- Focus Adverse reactions; Pharmacodynamics
- 16 Feb 2011 New trial record